Oleandrin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Oleandrin
Accession Number
DB12843
Type
Small Molecule
Groups
Experimental, Investigational
Description

Oleandrin has been used in trials studying the treatment of Lung Cancer and Chemotherapeutic Agent Toxicity.

Structure
Thumb
Synonyms
  • Anvirzel
  • Oleandrina
External IDs
NSC-692219
Categories
UNII
II95UDU7I4
CAS number
465-16-7
Weight
Average: 576.727
Monoisotopic: 576.329833126
Chemical Formula
C32H48O9
InChI Key
JLPDBLFIVFSOCC-XYXFTTADSA-N
InChI
InChI=1S/C32H48O9/c1-17-29(35)24(37-5)14-27(39-17)41-21-8-10-30(3)20(13-21)6-7-23-22(30)9-11-31(4)28(19-12-26(34)38-16-19)25(40-18(2)33)15-32(23,31)36/h12,17,20-25,27-29,35-36H,6-11,13-16H2,1-5H3/t17-,20+,21-,22-,23+,24-,25-,27-,28-,29-,30-,31+,32-/m0/s1
IUPAC Name
(1S,2S,5S,7R,10R,11S,13S,14R,15R)-11-hydroxy-5-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-2,15-dimethyl-14-(5-oxo-2,5-dihydrofuran-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl acetate
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
10-hydroxycamptothecinOleandrin may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Investigational
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideOleandrin may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-chloroethyl-3-sarcosinamide-1-nitrosoureaOleandrin may decrease the cardiotoxic activities of 2-chloroethyl-3-sarcosinamide-1-nitrosourea.Investigational
2-MethoxyestradiolOleandrin may decrease the cardiotoxic activities of 2-Methoxyestradiol.Investigational
3-MethoxybenzamideOleandrin may decrease the cardiotoxic activities of 3-Methoxybenzamide.Experimental
3,3'-diindolylmethaneOleandrin may decrease the cardiotoxic activities of 3,3'-diindolylmethane.Investigational
3,4-Dihydroxybenzoic AcidOleandrin may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.Experimental
6-O-benzylguanineOleandrin may decrease the cardiotoxic activities of 6-O-benzylguanine.Investigational
7-HydroxystaurosporineOleandrin may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.Experimental, Investigational
8-azaguanineOleandrin may decrease the cardiotoxic activities of 8-azaguanine.Experimental
9-aminocamptothecinOleandrin may decrease the cardiotoxic activities of 9-aminocamptothecin.Investigational
AbirateroneOleandrin may decrease the cardiotoxic activities of Abiraterone.Approved
AcebutololAcebutolol may increase the bradycardic activities of Oleandrin.Approved
AclarubicinOleandrin may decrease the cardiotoxic activities of Aclarubicin.Investigational
Acridine CarboxamideOleandrin may decrease the cardiotoxic activities of Acridine Carboxamide.Investigational
ActeosideOleandrin may decrease the cardiotoxic activities of Acteoside.Investigational
AfatinibOleandrin may decrease the cardiotoxic activities of Afatinib.Approved
AfimoxifeneOleandrin may decrease the cardiotoxic activities of Afimoxifene.Investigational
AlatrofloxacinOleandrin may decrease the cardiotoxic activities of Alatrofloxacin.Withdrawn
AlbendazoleOleandrin may decrease the cardiotoxic activities of Albendazole.Approved, Vet Approved
AlcuroniumAlcuronium may increase the arrhythmogenic activities of Oleandrin.Experimental
AldesleukinOleandrin may decrease the cardiotoxic activities of Aldesleukin.Approved
AlemtuzumabOleandrin may decrease the cardiotoxic activities of Alemtuzumab.Approved, Investigational
AlitretinoinOleandrin may decrease the cardiotoxic activities of Alitretinoin.Approved, Investigational
AlprenololAlprenolol may increase the bradycardic activities of Oleandrin.Approved, Withdrawn
AltretamineOleandrin may decrease the cardiotoxic activities of Altretamine.Approved
AlvocidibOleandrin may decrease the cardiotoxic activities of Alvocidib.Experimental, Investigational
AmikacinThe serum concentration of Oleandrin can be decreased when it is combined with Amikacin.Approved, Vet Approved
AmilorideThe therapeutic efficacy of Oleandrin can be decreased when used in combination with Amiloride.Approved
AminoglutethimideOleandrin may decrease the cardiotoxic activities of Aminoglutethimide.Approved, Investigational
Aminolevulinic acidOleandrin may decrease the cardiotoxic activities of Aminolevulinic acid.Approved
AmiodaroneThe serum concentration of Oleandrin can be increased when it is combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Oleandrin can be increased when it is combined with Amodiaquine.Approved, Investigational
AmonafideOleandrin may decrease the cardiotoxic activities of Amonafide.Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Oleandrin.Approved, Investigational
AmrubicinOleandrin may decrease the cardiotoxic activities of Amrubicin.Approved, Investigational
AmsacrineOleandrin may decrease the cardiotoxic activities of Amsacrine.Approved
AnagrelideOleandrin may decrease the cardiotoxic activities of Anagrelide.Approved
AnastrozoleOleandrin may decrease the cardiotoxic activities of Anastrozole.Approved, Investigational
AnecortaveOleandrin may decrease the cardiotoxic activities of Anecortave.Investigational
annamycinOleandrin may decrease the cardiotoxic activities of annamycin.Investigational
AP 12009Oleandrin may decrease the cardiotoxic activities of AP 12009.Investigational
AP24534Oleandrin may decrease the cardiotoxic activities of AP24534.Investigational
ApaziquoneOleandrin may decrease the cardiotoxic activities of Apaziquone.Investigational
ApramycinThe serum concentration of Oleandrin can be decreased when it is combined with Apramycin.Experimental, Vet Approved
ArbekacinThe serum concentration of Oleandrin can be decreased when it is combined with Arbekacin.Approved, Investigational
Arotinoid acidOleandrin may decrease the cardiotoxic activities of TTNPB.Experimental
ArotinololArotinolol may increase the bradycardic activities of Oleandrin.Approved, Investigational
Arsanilic acidOleandrin may decrease the cardiotoxic activities of Arsanilic acid.Experimental, Vet Approved
Arsenic trioxideOleandrin may decrease the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
AsparaginaseOleandrin may decrease the cardiotoxic activities of Asparaginase.Approved
AtenololAtenolol may increase the bradycardic activities of Oleandrin.Approved
AtracuriumAtracurium may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
Atracurium besylateAtracurium besylate may increase the arrhythmogenic activities of Oleandrin.Approved
AxitinibOleandrin may decrease the cardiotoxic activities of Axitinib.Approved, Investigational
AzacitidineOleandrin may decrease the cardiotoxic activities of Azacitidine.Approved, Investigational
AzathioprineOleandrin may decrease the cardiotoxic activities of Azathioprine.Approved
Azelaic AcidOleandrin may decrease the cardiotoxic activities of Azelaic Acid.Approved
AzithromycinThe serum concentration of Oleandrin can be increased when it is combined with Azithromycin.Approved
BalsalazideThe serum concentration of Oleandrin can be decreased when it is combined with Balsalazide.Approved, Investigational
BatimastatOleandrin may decrease the cardiotoxic activities of Batimastat.Experimental
BefunololBefunolol may increase the bradycardic activities of Oleandrin.Experimental
BekanamycinThe serum concentration of Oleandrin can be decreased when it is combined with Bekanamycin.Experimental
BelinostatOleandrin may decrease the cardiotoxic activities of Belinostat.Approved, Investigational
BelotecanOleandrin may decrease the cardiotoxic activities of Belotecan.Investigational
BendamustineOleandrin may decrease the cardiotoxic activities of Bendamustine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Oleandrin.Approved
BesifloxacinOleandrin may decrease the cardiotoxic activities of Besifloxacin.Approved
BetaxololBetaxolol may increase the bradycardic activities of Oleandrin.Approved
BevacizumabOleandrin may decrease the cardiotoxic activities of Bevacizumab.Approved, Investigational
BevantololBevantolol may increase the bradycardic activities of Oleandrin.Approved
BexaroteneOleandrin may decrease the cardiotoxic activities of Bexarotene.Approved, Investigational
BicalutamideOleandrin may decrease the cardiotoxic activities of Bicalutamide.Approved
BinetrakinOleandrin may decrease the cardiotoxic activities of Binetrakin.Investigational
BisoprololBisoprolol may increase the bradycardic activities of Oleandrin.Approved
BizelesinOleandrin may decrease the cardiotoxic activities of Bizelesin.Investigational
BleomycinOleandrin may decrease the cardiotoxic activities of Bleomycin.Approved
BlinatumomabOleandrin may decrease the cardiotoxic activities of Blinatumomab.Approved
BopindololBopindolol may increase the bradycardic activities of Oleandrin.Approved
BortezomibOleandrin may decrease the cardiotoxic activities of Bortezomib.Approved, Investigational
BosutinibOleandrin may decrease the cardiotoxic activities of Bosutinib.Approved
Brentuximab vedotinOleandrin may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
BroxuridineOleandrin may decrease the cardiotoxic activities of Broxuridine.Investigational
Bryostatin 1Oleandrin may decrease the cardiotoxic activities of Bryostatin 1.Investigational
BSI-201Oleandrin may decrease the cardiotoxic activities of BSI-201.Investigational
BucindololBucindolol may increase the bradycardic activities of Oleandrin.Investigational
BufuralolBufuralol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Oleandrin.Approved
BupranololBupranolol may increase the bradycardic activities of Oleandrin.Approved
BusulfanOleandrin may decrease the cardiotoxic activities of Busulfan.Approved, Investigational
Buthionine SulfoximineOleandrin may decrease the cardiotoxic activities of Buthionine Sulfoximine.Investigational
CabazitaxelOleandrin may decrease the cardiotoxic activities of Cabazitaxel.Approved
CabergolineOleandrin may decrease the cardiotoxic activities of Cabergoline.Approved
CabozantinibOleandrin may decrease the cardiotoxic activities of Cabozantinib.Approved
CalcidiolCalcidiol may increase the arrhythmogenic activities of Oleandrin.Approved, Nutraceutical
CalcipotriolOleandrin may decrease the cardiotoxic activities of Calcipotriol.Approved
CalciumCalcium may increase the arrhythmogenic activities of Oleandrin.Approved, Nutraceutical
Calcium AcetateCalcium Acetate may increase the arrhythmogenic activities of Oleandrin.Approved
Calcium CarbonateCalcium Carbonate may increase the arrhythmogenic activities of Oleandrin.Approved
Calcium CitrateCalcium Citrate may increase the arrhythmogenic activities of Oleandrin.Approved
Calcium glubionateCalcium glubionate may increase the arrhythmogenic activities of Oleandrin.Approved
Calcium GluceptateCalcium Gluceptate may increase the arrhythmogenic activities of Oleandrin.Approved
Calcium gluconateCalcium gluconate may increase the arrhythmogenic activities of Oleandrin.Approved, Vet Approved
Calcium lactateCalcium lactate may increase the arrhythmogenic activities of Oleandrin.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate may increase the arrhythmogenic activities of Oleandrin.Experimental
Calcium laevulateCalcium laevulate may increase the arrhythmogenic activities of Oleandrin.Experimental
Calcium pangamateCalcium pangamate may increase the arrhythmogenic activities of Oleandrin.Experimental
Calcium PhosphateCalcium Phosphate may increase the arrhythmogenic activities of Oleandrin.Approved
CamptothecinOleandrin may decrease the cardiotoxic activities of Camptothecin.Experimental
CanertinibOleandrin may decrease the cardiotoxic activities of Canertinib.Investigational
CapecitabineOleandrin may decrease the cardiotoxic activities of Capecitabine.Approved, Investigational
CarbimazoleThe serum concentration of Oleandrin can be increased when it is combined with Carbimazole.Approved, Investigational
CarbomycinThe serum concentration of Oleandrin can be increased when it is combined with Carbomycin.Vet Approved
CarboplatinOleandrin may decrease the cardiotoxic activities of Carboplatin.Approved
CarboquoneOleandrin may decrease the cardiotoxic activities of Carboquone.Experimental
CarboxyamidotriazoleOleandrin may decrease the cardiotoxic activities of Carboxyamidotriazole.Investigational
CarfilzomibOleandrin may decrease the cardiotoxic activities of Carfilzomib.Approved
CarmofurOleandrin may decrease the cardiotoxic activities of Carmofur.Withdrawn
CarmustineOleandrin may decrease the cardiotoxic activities of Carmustine.Approved
CarteololCarteolol may increase the bradycardic activities of Oleandrin.Approved
CarvedilolCarvedilol may increase the bradycardic activities of Oleandrin.Approved, Investigational
CaseinCasein may increase the arrhythmogenic activities of Oleandrin.Approved
CatumaxomabOleandrin may decrease the cardiotoxic activities of Catumaxomab.Approved, Investigational
CediranibOleandrin may decrease the cardiotoxic activities of Cediranib.Investigational
CeliprololCeliprolol may increase the bradycardic activities of Oleandrin.Approved, Investigational
CeritinibOleandrin may decrease the cardiotoxic activities of Ceritinib.Approved
CetuximabOleandrin may decrease the cardiotoxic activities of Cetuximab.Approved
ChlorambucilOleandrin may decrease the cardiotoxic activities of Chlorambucil.Approved
ChloroquineThe serum concentration of Oleandrin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Oleandrin.Approved, Vet Approved
ChlorotrianiseneOleandrin may decrease the cardiotoxic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Oleandrin.Approved
CholesterolOleandrin may decrease the cardiotoxic activities of Cholesterol.Experimental, Investigational
CholestyramineCholestyramine can cause a decrease in the absorption of Oleandrin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinOleandrin may decrease the cardiotoxic activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinOleandrin may decrease the cardiotoxic activities of Ciprofloxacin.Approved, Investigational
CisatracuriumCisatracurium may increase the arrhythmogenic activities of Oleandrin.Approved, Experimental
Cisatracurium besylateCisatracurium besylate may increase the arrhythmogenic activities of Oleandrin.Approved
CisplatinOleandrin may decrease the cardiotoxic activities of Cisplatin.Approved
CladribineOleandrin may decrease the cardiotoxic activities of Cladribine.Approved, Investigational
ClarithromycinThe serum concentration of Oleandrin can be increased when it is combined with Clarithromycin.Approved
ClofarabineOleandrin may decrease the cardiotoxic activities of Clofarabine.Approved, Investigational
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Oleandrin.Approved
CloranololCloranolol may increase the bradycardic activities of Oleandrin.Experimental
ColchicineOleandrin may decrease the cardiotoxic activities of Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Oleandrin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Oleandrin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CombretastatinOleandrin may decrease the cardiotoxic activities of Combretastatin.Investigational
CordycepinOleandrin may decrease the cardiotoxic activities of Cordycepin.Investigational
Coumermycin A1Oleandrin may decrease the cardiotoxic activities of Coumermycin A1.Experimental
CrenolanibOleandrin may decrease the cardiotoxic activities of Crenolanib.Investigational
CrizotinibOleandrin may decrease the cardiotoxic activities of Crizotinib.Approved
CurcuminOleandrin may decrease the cardiotoxic activities of Curcumin.Investigational
CyclopenthiazideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Oleandrin.Experimental
CyclophosphamideOleandrin may decrease the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
Cyproterone acetateOleandrin may decrease the cardiotoxic activities of Cyproterone acetate.Approved, Investigational
CytarabineOleandrin may decrease the cardiotoxic activities of Cytarabine.Approved, Investigational
DabrafenibOleandrin may decrease the cardiotoxic activities of Dabrafenib.Approved
DacarbazineOleandrin may decrease the cardiotoxic activities of Dacarbazine.Approved, Investigational
DactinomycinOleandrin may decrease the cardiotoxic activities of Dactinomycin.Approved
DaratumumabOleandrin may decrease the cardiotoxic activities of Daratumumab.Approved
DasatinibOleandrin may decrease the cardiotoxic activities of Dasatinib.Approved, Investigational
DaunorubicinOleandrin may decrease the cardiotoxic activities of Daunorubicin.Approved
DecamethoniumDecamethonium may increase the arrhythmogenic activities of Oleandrin.Approved
DecitabineOleandrin may decrease the cardiotoxic activities of Decitabine.Approved, Investigational
DemecolcineOleandrin may decrease the cardiotoxic activities of Demecolcine.Experimental
Denileukin diftitoxOleandrin may decrease the cardiotoxic activities of Denileukin diftitox.Approved, Investigational
DeoxyspergualinOleandrin may decrease the cardiotoxic activities of Deoxyspergualin.Investigational
DexamethasoneOleandrin may decrease the cardiotoxic activities of Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneOleandrin may decrease the cardiotoxic activities of Dexrazoxane.Approved, Withdrawn
DianhydrogalactitolOleandrin may decrease the cardiotoxic activities of Dianhydrogalactitol.Investigational
DibekacinThe serum concentration of Oleandrin can be decreased when it is combined with Dibekacin.Experimental
DidoxOleandrin may decrease the cardiotoxic activities of Didox.Investigational
DienogestOleandrin may decrease the cardiotoxic activities of Dienogest.Approved
diethylnorspermineOleandrin may decrease the cardiotoxic activities of diethylnorspermine.Investigational
DiethylstilbestrolOleandrin may decrease the cardiotoxic activities of Diethylstilbestrol.Approved, Investigational
DihydrostreptomycinThe serum concentration of Oleandrin can be decreased when it is combined with Dihydrostreptomycin.Investigational, Vet Approved
DihydrotachysterolDihydrotachysterol may increase the arrhythmogenic activities of Oleandrin.Approved
DiltiazemDiltiazem may increase the atrioventricular blocking (AV block) activities of Oleandrin.Approved
DinutuximabOleandrin may decrease the cardiotoxic activities of Dinutuximab.Approved
DocetaxelOleandrin may decrease the cardiotoxic activities of Docetaxel.Approved, Investigational
Dolastatin 10Oleandrin may decrease the cardiotoxic activities of Dolastatin 10.Investigational
Domoic AcidDomoic Acid may increase the arrhythmogenic activities of Oleandrin.Experimental
Doxacurium chlorideDoxacurium chloride may increase the arrhythmogenic activities of Oleandrin.Approved
DoxercalciferolDoxercalciferol may increase the arrhythmogenic activities of Oleandrin.Approved
DoxifluridineOleandrin may decrease the cardiotoxic activities of Doxifluridine.Investigational
DoxorubicinOleandrin may decrease the cardiotoxic activities of Doxorubicin.Approved, Investigational
DuligotuzumabOleandrin may decrease the cardiotoxic activities of Duligotuzumab.Investigational
EcabetOleandrin may decrease the cardiotoxic activities of Ecabet.Approved, Investigational
EdrecolomabOleandrin may decrease the cardiotoxic activities of Edrecolomab.Experimental, Investigational
EdrophoniumEdrophonium may increase the atrioventricular blocking (AV block) activities of Oleandrin.Approved
EfaproxiralOleandrin may decrease the cardiotoxic activities of Efaproxiral.Investigational
EfatutazoneOleandrin may decrease the cardiotoxic activities of Efatutazone.Investigational
EflornithineOleandrin may decrease the cardiotoxic activities of Eflornithine.Approved, Withdrawn
EG009Oleandrin may decrease the cardiotoxic activities of EG009.Investigational
ElsamitrucinOleandrin may decrease the cardiotoxic activities of Elsamitrucin.Investigational
EndostatinOleandrin may decrease the cardiotoxic activities of Endostatin.Investigational
EnoxacinOleandrin may decrease the cardiotoxic activities of Enoxacin.Approved, Investigational
EnrofloxacinOleandrin may decrease the cardiotoxic activities of Enrofloxacin.Vet Approved
EntinostatOleandrin may decrease the cardiotoxic activities of Entinostat.Investigational
EpanololEpanolol may increase the bradycardic activities of Oleandrin.Experimental
Epigallocatechin GallateOleandrin may decrease the cardiotoxic activities of Epigallocatechin Gallate.Investigational
EpirubicinOleandrin may decrease the cardiotoxic activities of Epirubicin.Approved
EplerenoneThe therapeutic efficacy of Oleandrin can be decreased when used in combination with Eplerenone.Approved
EpofolateOleandrin may decrease the cardiotoxic activities of Epofolate.Investigational
ErgocalciferolErgocalciferol may increase the arrhythmogenic activities of Oleandrin.Approved, Nutraceutical
EribulinOleandrin may decrease the cardiotoxic activities of Eribulin.Approved, Investigational
ErlotinibOleandrin may decrease the cardiotoxic activities of Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Oleandrin can be increased when it is combined with Erythromycin.Approved, Vet Approved
EsmololEsmolol may increase the bradycardic activities of Oleandrin.Approved
EstramustineOleandrin may decrease the cardiotoxic activities of Estramustine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Oleandrin.Approved
EtanidazoleOleandrin may decrease the cardiotoxic activities of Etanidazole.Investigational
Ethiodized oilOleandrin may decrease the cardiotoxic activities of Ethiodized oil.Approved
Ethyl carbamateOleandrin may decrease the cardiotoxic activities of Ethyl carbamate.Withdrawn
EtoglucidOleandrin may decrease the cardiotoxic activities of Etoglucid.Experimental
EtoposideOleandrin may decrease the cardiotoxic activities of Etoposide.Approved
EverolimusOleandrin may decrease the cardiotoxic activities of Everolimus.Approved
ExatecanOleandrin may decrease the cardiotoxic activities of Exatecan.Investigational
ExemestaneOleandrin may decrease the cardiotoxic activities of Exemestane.Approved, Investigational
exisulindOleandrin may decrease the cardiotoxic activities of exisulind.Investigational
FenretinideOleandrin may decrease the cardiotoxic activities of Fenretinide.Investigational
FiacitabineOleandrin may decrease the cardiotoxic activities of Fiacitabine.Investigational
FleroxacinOleandrin may decrease the cardiotoxic activities of Fleroxacin.Approved
FloxuridineOleandrin may decrease the cardiotoxic activities of Floxuridine.Approved
FludarabineOleandrin may decrease the cardiotoxic activities of Fludarabine.Approved
FlumequineOleandrin may decrease the cardiotoxic activities of Flumequine.Withdrawn
FluorouracilOleandrin may decrease the cardiotoxic activities of Fluorouracil.Approved
FlutamideOleandrin may decrease the cardiotoxic activities of Flutamide.Approved
FormestaneOleandrin may decrease the cardiotoxic activities of Formestane.Approved, Investigational, Withdrawn
FormycinOleandrin may decrease the cardiotoxic activities of Formycin.Experimental
FosbretabulinOleandrin may decrease the cardiotoxic activities of Fosbretabulin.Investigational
FotemustineOleandrin may decrease the cardiotoxic activities of Fotemustine.Experimental, Investigational
FramycetinThe serum concentration of Oleandrin can be decreased when it is combined with Framycetin.Approved
FulvestrantOleandrin may decrease the cardiotoxic activities of Fulvestrant.Approved, Investigational
FumagillinOleandrin may decrease the cardiotoxic activities of Fumagillin.Experimental
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Oleandrin.Approved, Vet Approved
GallamineGallamine may increase the arrhythmogenic activities of Oleandrin.Experimental
Gallamine TriethiodideGallamine Triethiodide may increase the arrhythmogenic activities of Oleandrin.Approved
Gallium nitrateOleandrin may decrease the cardiotoxic activities of Gallium nitrate.Approved, Investigational
GarenoxacinOleandrin may decrease the cardiotoxic activities of Garenoxacin.Investigational
GatifloxacinOleandrin may decrease the cardiotoxic activities of Gatifloxacin.Approved, Investigational
GefitinibOleandrin may decrease the cardiotoxic activities of Gefitinib.Approved, Investigational
GeldanamycinOleandrin may decrease the cardiotoxic activities of Geldanamycin.Experimental, Investigational
GemcitabineOleandrin may decrease the cardiotoxic activities of Gemcitabine.Approved
GemifloxacinOleandrin may decrease the cardiotoxic activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinOleandrin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.Approved
GeneticinThe serum concentration of Oleandrin can be decreased when it is combined with Geneticin.Experimental
GenisteinOleandrin may decrease the cardiotoxic activities of Genistein.Investigational
GentamicinThe serum concentration of Oleandrin can be decreased when it is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of Oleandrin can be decreased when it is combined with GENTAMICIN C1A.Experimental
Ginsenoside COleandrin may decrease the cardiotoxic activities of Ginsenoside C.Nutraceutical
GoserelinOleandrin may decrease the cardiotoxic activities of Goserelin.Approved
GPX-150The serum concentration of Oleandrin can be decreased when it is combined with GPX-150.Investigational
GrepafloxacinOleandrin may decrease the cardiotoxic activities of Grepafloxacin.Investigational, Withdrawn
GS 0573Oleandrin may decrease the cardiotoxic activities of GS 0573.Investigational
GusperimusOleandrin may decrease the cardiotoxic activities of Gusperimus.Investigational
HadacidinOleandrin may decrease the cardiotoxic activities of Hadacidin.Experimental
HalofuginoneOleandrin may decrease the cardiotoxic activities of Halofuginone.Investigational, Vet Approved
HexestrolOleandrin may decrease the cardiotoxic activities of Hexestrol.Withdrawn
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Oleandrin.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Oleandrin.Approved, Investigational
HydroxychloroquineThe serum concentration of Oleandrin can be increased when it is combined with Hydroxychloroquine.Approved
Hydroxyprogesterone caproateOleandrin may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.Approved
HydroxyureaOleandrin may decrease the cardiotoxic activities of Hydroxyurea.Approved
Hygromycin BThe serum concentration of Oleandrin can be decreased when it is combined with Hygromycin B.Vet Approved
HypericinOleandrin may decrease the cardiotoxic activities of Hypericin.Investigational
IbrutinibOleandrin may decrease the cardiotoxic activities of Ibrutinib.Approved
IdarubicinOleandrin may decrease the cardiotoxic activities of Idarubicin.Approved
IdelalisibOleandrin may decrease the cardiotoxic activities of Idelalisib.Approved
IfosfamideOleandrin may decrease the cardiotoxic activities of Ifosfamide.Approved
ImatinibOleandrin may decrease the cardiotoxic activities of Imatinib.Approved
ImiquimodOleandrin may decrease the cardiotoxic activities of Imiquimod.Approved, Investigational
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Oleandrin.Approved
IndenololIndenolol may increase the bradycardic activities of Oleandrin.Withdrawn
IndirubinOleandrin may decrease the cardiotoxic activities of Indirubin.Investigational
Indole-3-carbinolOleandrin may decrease the cardiotoxic activities of Indole-3-carbinol.Investigational
InfigratinibOleandrin may decrease the cardiotoxic activities of Infigratinib.Investigational
IniparibOleandrin may decrease the cardiotoxic activities of Iniparib.Experimental, Investigational
INNO-206The serum concentration of Oleandrin can be decreased when it is combined with INNO-206.Investigational
Interferon beta-1aOleandrin may decrease the cardiotoxic activities of Interferon beta-1a.Approved, Investigational
IobenguaneOleandrin may decrease the cardiotoxic activities of Iobenguane.Approved, Investigational
IpilimumabOleandrin may decrease the cardiotoxic activities of Ipilimumab.Approved
IrinotecanOleandrin may decrease the cardiotoxic activities of Irinotecan.Approved, Investigational
IrofulvenOleandrin may decrease the cardiotoxic activities of Irofulven.Investigational
IrsogladineOleandrin may decrease the cardiotoxic activities of Irsogladine.Investigational
IsepamicinThe serum concentration of Oleandrin can be decreased when it is combined with Isepamicin.Experimental
IsosorbideOleandrin may decrease the cardiotoxic activities of Isosorbide.Approved, Investigational
ItraconazoleThe serum concentration of Oleandrin can be increased when it is combined with Itraconazole.Approved, Investigational
IxabepiloneOleandrin may decrease the cardiotoxic activities of Ixabepilone.Approved, Investigational
IxazomibOleandrin may decrease the cardiotoxic activities of Ixazomib.Approved
JosamycinThe serum concentration of Oleandrin can be increased when it is combined with Josamycin.Approved, Investigational
KanamycinThe serum concentration of Oleandrin can be decreased when it is combined with Kanamycin.Approved, Investigational, Vet Approved
KaolinThe serum concentration of Oleandrin can be decreased when it is combined with Kaolin.Approved
KitasamycinThe serum concentration of Oleandrin can be increased when it is combined with Kitasamycin.Experimental
KOS-1584Oleandrin may decrease the cardiotoxic activities of KOS-1584.Investigational
KRN-7000Oleandrin may decrease the cardiotoxic activities of KRN-7000.Investigational
L-alanosineOleandrin may decrease the cardiotoxic activities of L-alanosine.Investigational
LabetalolLabetalol may increase the bradycardic activities of Oleandrin.Approved
LandiololLandiolol may increase the bradycardic activities of Oleandrin.Investigational
LanreotideOleandrin may decrease the cardiotoxic activities of Lanreotide.Approved
LapatinibOleandrin may decrease the cardiotoxic activities of Lapatinib.Approved, Investigational
LCL-161Oleandrin may decrease the cardiotoxic activities of LCL-161.Investigational
LeflunomideOleandrin may decrease the cardiotoxic activities of Leflunomide.Approved, Investigational
LenalidomideOleandrin may decrease the cardiotoxic activities of Lenalidomide.Approved
LentinanOleandrin may decrease the cardiotoxic activities of Lentinan.Experimental, Investigational
LenvatinibOleandrin may decrease the cardiotoxic activities of Lenvatinib.Approved
LetrozoleOleandrin may decrease the cardiotoxic activities of Letrozole.Approved, Investigational
LeuprolideOleandrin may decrease the cardiotoxic activities of Leuprolide.Approved, Investigational
LevobunololLevobunolol may increase the bradycardic activities of Oleandrin.Approved
LevofloxacinOleandrin may decrease the cardiotoxic activities of Levofloxacin.Approved, Investigational
LiarozoleOleandrin may decrease the cardiotoxic activities of Liarozole.Investigational
LicoriceThe risk or severity of adverse effects can be increased when Licorice is combined with Oleandrin.Approved
LomefloxacinOleandrin may decrease the cardiotoxic activities of Lomefloxacin.Approved, Investigational
LometrexolOleandrin may decrease the cardiotoxic activities of Lometrexol.Investigational
LomustineOleandrin may decrease the cardiotoxic activities of Lomustine.Approved
LonidamineOleandrin may decrease the cardiotoxic activities of Lonidamine.Approved, Investigational
LurtotecanOleandrin may decrease the cardiotoxic activities of Lurtotecan.Investigational
LycopeneOleandrin may decrease the cardiotoxic activities of Lycopene.Approved
MafosfamideOleandrin may decrease the cardiotoxic activities of Mafosfamide.Investigational
MannosulfanOleandrin may decrease the cardiotoxic activities of Mannosulfan.Experimental
MasitinibOleandrin may decrease the cardiotoxic activities of Masitinib.Investigational, Vet Approved
MasoprocolOleandrin may decrease the cardiotoxic activities of Masoprocol.Approved, Investigational
MaxacalcitolOleandrin may decrease the cardiotoxic activities of Maxacalcitol.Approved, Investigational
MebendazoleOleandrin may decrease the cardiotoxic activities of Mebendazole.Approved, Vet Approved
MechlorethamineOleandrin may decrease the cardiotoxic activities of Mechlorethamine.Approved
MedrogestoneOleandrin may decrease the cardiotoxic activities of Medrogestone.Approved
Medroxyprogesterone acetateOleandrin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateOleandrin may decrease the cardiotoxic activities of Megestrol acetate.Approved, Vet Approved
MelphalanOleandrin may decrease the cardiotoxic activities of Melphalan.Approved
MepindololMepindolol may increase the bradycardic activities of Oleandrin.Experimental
MequinolOleandrin may decrease the cardiotoxic activities of Mequinol.Approved
MercaptopurineOleandrin may decrease the cardiotoxic activities of Mercaptopurine.Approved
MerestinibOleandrin may decrease the cardiotoxic activities of Merestinib.Investigational
MesalazineThe serum concentration of Oleandrin can be decreased when it is combined with Mesalazine.Approved
MethimazoleThe serum concentration of Oleandrin can be increased when it is combined with Methimazole.Approved
MethotrexateOleandrin may decrease the cardiotoxic activities of Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Oleandrin.Approved
Methyl aminolevulinateOleandrin may decrease the cardiotoxic activities of Methyl aminolevulinate.Approved
MethylprednisoloneOleandrin may decrease the cardiotoxic activities of Methylprednisolone.Approved, Vet Approved
MethylselenocysteineOleandrin may decrease the cardiotoxic activities of Methylselenocysteine.Investigational
MethyltestosteroneOleandrin may decrease the cardiotoxic activities of Methyltestosterone.Approved
MethylthiouracilThe serum concentration of Oleandrin can be increased when it is combined with Methylthiouracil.Experimental
MetipranololMetipranolol may increase the bradycardic activities of Oleandrin.Approved
MetocurineMetocurine may increase the arrhythmogenic activities of Oleandrin.Approved
Metocurine IodideMetocurine Iodide may increase the arrhythmogenic activities of Oleandrin.Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Oleandrin.Approved
MetoprineOleandrin may decrease the cardiotoxic activities of Metoprine.Experimental
MetoprololMetoprolol may increase the bradycardic activities of Oleandrin.Approved, Investigational
MetrizamideThe serum concentration of Oleandrin can be decreased when it is combined with Metrizamide.Approved
MicronomicinThe serum concentration of Oleandrin can be decreased when it is combined with Micronomicin.Experimental
MidodrineOleandrin may increase the bradycardic activities of Midodrine.Approved
MidostaurinOleandrin may decrease the cardiotoxic activities of Midostaurin.Approved
MiltefosineOleandrin may decrease the cardiotoxic activities of Miltefosine.Approved
MisonidazoleOleandrin may decrease the cardiotoxic activities of Misonidazole.Investigational
MitobronitolOleandrin may decrease the cardiotoxic activities of Mitobronitol.Experimental
MitoguazoneOleandrin may decrease the cardiotoxic activities of Mitoguazone.Investigational
MitolactolOleandrin may decrease the cardiotoxic activities of Mitolactol.Investigational
MitomycinOleandrin may decrease the cardiotoxic activities of Mitomycin.Approved
MitotaneOleandrin may decrease the cardiotoxic activities of Mitotane.Approved
MitoxantroneOleandrin may decrease the cardiotoxic activities of Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the arrhythmogenic activities of Oleandrin.Approved
MizoribineOleandrin may decrease the cardiotoxic activities of Mizoribine.Investigational
MLN576Oleandrin may decrease the cardiotoxic activities of MLN576.Investigational
MolgramostimOleandrin may decrease the cardiotoxic activities of Molgramostim.Investigational
motexafin gadoliniumOleandrin may decrease the cardiotoxic activities of motexafin gadolinium.Investigational
MoxifloxacinOleandrin may decrease the cardiotoxic activities of Moxifloxacin.Approved, Investigational
Mycophenolic acidOleandrin may decrease the cardiotoxic activities of Mycophenolic acid.Approved
NadifloxacinOleandrin may decrease the cardiotoxic activities of Nadifloxacin.Investigational
NadololNadolol may increase the bradycardic activities of Oleandrin.Approved
Nalidixic AcidOleandrin may decrease the cardiotoxic activities of Nalidixic Acid.Approved, Investigational
NamitecanOleandrin may decrease the cardiotoxic activities of Namitecan.Investigational
NavitoclaxOleandrin may decrease the cardiotoxic activities of Navitoclax.Investigational
NeamineThe serum concentration of Oleandrin can be decreased when it is combined with Neamine.Experimental
NebularineOleandrin may decrease the cardiotoxic activities of Nebularine.Experimental
NecitumumabOleandrin may decrease the cardiotoxic activities of Necitumumab.Approved
NedaplatinOleandrin may decrease the cardiotoxic activities of Nedaplatin.Approved, Investigational
NelarabineOleandrin may decrease the cardiotoxic activities of Nelarabine.Approved, Investigational
NeomycinThe serum concentration of Oleandrin can be decreased when it is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinNeosaxitoxin may increase the arrhythmogenic activities of Oleandrin.Investigational
NetilmicinThe serum concentration of Oleandrin can be decreased when it is combined with Netilmicin.Approved, Investigational
NiguldipineOleandrin may decrease the cardiotoxic activities of Niguldipine.Experimental
NilotinibOleandrin may decrease the cardiotoxic activities of Nilotinib.Approved, Investigational
NilutamideOleandrin may decrease the cardiotoxic activities of Nilutamide.Approved
NimustineOleandrin may decrease the cardiotoxic activities of Nimustine.Investigational
NintedanibOleandrin may decrease the cardiotoxic activities of Nintedanib.Approved
NiraparibOleandrin may decrease the cardiotoxic activities of Niraparib.Approved, Investigational
NivolumabOleandrin may decrease the cardiotoxic activities of Nivolumab.Approved
nocodazoleOleandrin may decrease the cardiotoxic activities of nocodazole.Experimental
NolatrexedOleandrin may decrease the cardiotoxic activities of Nolatrexed.Investigational
NorfloxacinOleandrin may decrease the cardiotoxic activities of Norfloxacin.Approved
ObinutuzumabOleandrin may decrease the cardiotoxic activities of Obinutuzumab.Approved
OblimersenOleandrin may decrease the cardiotoxic activities of Oblimersen.Experimental, Investigational
OBP-801Oleandrin may decrease the cardiotoxic activities of OBP-801.Investigational
OctreotideOleandrin may decrease the cardiotoxic activities of Octreotide.Approved, Investigational
OfatumumabOleandrin may decrease the cardiotoxic activities of Ofatumumab.Approved
OfloxacinOleandrin may decrease the cardiotoxic activities of Ofloxacin.Approved
OglufanideOleandrin may decrease the cardiotoxic activities of Oglufanide.Investigational
OlaparibOleandrin may decrease the cardiotoxic activities of Olaparib.Approved
OleandomycinThe serum concentration of Oleandrin can be increased when it is combined with Oleandomycin.Vet Approved
OlsalazineThe serum concentration of Oleandrin can be decreased when it is combined with Olsalazine.Approved
OltiprazOleandrin may decrease the cardiotoxic activities of Oltipraz.Investigational
Omacetaxine mepesuccinateOleandrin may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.Approved
OnapristoneOleandrin may decrease the cardiotoxic activities of Onapristone.Investigational
OprelvekinOleandrin may decrease the cardiotoxic activities of Oprelvekin.Approved, Investigational
OsimertinibOleandrin may decrease the cardiotoxic activities of Osimertinib.Approved
OxaliplatinOleandrin may decrease the cardiotoxic activities of Oxaliplatin.Approved, Investigational
Oxolinic acidOleandrin may decrease the cardiotoxic activities of Oxolinic acid.Experimental
OxprenololOxprenolol may increase the bradycardic activities of Oleandrin.Approved
PaclitaxelOleandrin may decrease the cardiotoxic activities of Paclitaxel.Approved, Vet Approved
Paclitaxel poliglumexOleandrin may decrease the cardiotoxic activities of Paclitaxel poliglumex.Experimental, Investigational
PalbociclibOleandrin may decrease the cardiotoxic activities of Palbociclib.Approved
PalifosfamideOleandrin may decrease the cardiotoxic activities of Palifosfamide.Investigational
PamidronateOleandrin may decrease the cardiotoxic activities of Pamidronate.Approved
PancuroniumPancuronium may increase the arrhythmogenic activities of Oleandrin.Approved
PanitumumabOleandrin may decrease the cardiotoxic activities of Panitumumab.Approved, Investigational
PanobinostatOleandrin may decrease the cardiotoxic activities of Panobinostat.Approved, Investigational
Parathyroid hormoneThe risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Oleandrin.Approved, Investigational
ParicalcitolParicalcitol may increase the arrhythmogenic activities of Oleandrin.Approved, Investigational
ParomomycinThe serum concentration of Oleandrin can be decreased when it is combined with Paromomycin.Approved, Investigational
PatupiloneOleandrin may decrease the cardiotoxic activities of Patupilone.Experimental, Investigational
PazopanibOleandrin may decrease the cardiotoxic activities of Pazopanib.Approved
PazufloxacinOleandrin may decrease the cardiotoxic activities of Pazufloxacin.Investigational
PefloxacinOleandrin may decrease the cardiotoxic activities of Pefloxacin.Approved
PegaspargaseOleandrin may decrease the cardiotoxic activities of Pegaspargase.Approved, Investigational
PembrolizumabOleandrin may decrease the cardiotoxic activities of Pembrolizumab.Approved
PemetrexedOleandrin may decrease the cardiotoxic activities of Pemetrexed.Approved, Investigational
PenbutololPenbutolol may increase the bradycardic activities of Oleandrin.Approved, Investigational
PenclomedineOleandrin may decrease the cardiotoxic activities of Penclomedine.Investigational
PentostatinOleandrin may decrease the cardiotoxic activities of Pentostatin.Approved, Investigational
PertuzumabOleandrin may decrease the cardiotoxic activities of Pertuzumab.Approved
Phenethyl IsothiocyanateOleandrin may decrease the cardiotoxic activities of Phenethyl Isothiocyanate.Investigational
Phenylacetic acidOleandrin may decrease the cardiotoxic activities of Phenylacetic acid.Approved
Phenylbutyric acidOleandrin may decrease the cardiotoxic activities of Phenylbutyric acid.Approved, Investigational
PindololPindolol may increase the bradycardic activities of Oleandrin.Approved
PinometostatOleandrin may decrease the cardiotoxic activities of Pinometostat.Investigational
PipecuroniumPipecuronium may increase the arrhythmogenic activities of Oleandrin.Approved
PipobromanOleandrin may decrease the cardiotoxic activities of Pipobroman.Approved
PirarubicinOleandrin may decrease the cardiotoxic activities of Pirarubicin.Investigational
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Oleandrin.Experimental
PirfenidoneOleandrin may decrease the cardiotoxic activities of Pirfenidone.Approved, Investigational
PirlindoleOleandrin may decrease the cardiotoxic activities of Pirlindole.Approved
PixantroneOleandrin may decrease the cardiotoxic activities of Pixantrone.Approved, Investigational
PlazomicinThe serum concentration of Oleandrin can be decreased when it is combined with Plazomicin.Investigational
PlevitrexedOleandrin may decrease the cardiotoxic activities of Plevitrexed.Investigational
PlicamycinOleandrin may decrease the cardiotoxic activities of Plicamycin.Approved, Investigational, Withdrawn
PodofiloxOleandrin may decrease the cardiotoxic activities of Podofilox.Approved
PodophyllinOleandrin may decrease the cardiotoxic activities of Podophyllin.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Oleandrin.Approved
PomalidomideOleandrin may decrease the cardiotoxic activities of Pomalidomide.Approved
PonatinibOleandrin may decrease the cardiotoxic activities of Ponatinib.Approved
Porfimer sodiumOleandrin may decrease the cardiotoxic activities of Porfimer sodium.Approved, Investigational
porfiromycinOleandrin may decrease the cardiotoxic activities of porfiromycin.Investigational
PractololPractolol may increase the bradycardic activities of Oleandrin.Approved
PralatrexateOleandrin may decrease the cardiotoxic activities of Pralatrexate.Approved
PrednimustineOleandrin may decrease the cardiotoxic activities of Prednimustine.Investigational
PrednisoloneOleandrin may decrease the cardiotoxic activities of Prednisolone.Approved, Vet Approved
PrednisoneOleandrin may decrease the cardiotoxic activities of Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Oleandrin can be increased when it is combined with Primaquine.Approved
ProcarbazineOleandrin may decrease the cardiotoxic activities of Procarbazine.Approved
PropafenoneThe serum concentration of Oleandrin can be increased when it is combined with Propafenone.Approved
PropranololPropranolol may increase the bradycardic activities of Oleandrin.Approved, Investigational
PropylthiouracilThe serum concentration of Oleandrin can be increased when it is combined with Propylthiouracil.Approved
PrulifloxacinOleandrin may decrease the cardiotoxic activities of Prulifloxacin.Investigational
PuromycinOleandrin may decrease the cardiotoxic activities of Puromycin.Experimental
PyrantelPyrantel may increase the arrhythmogenic activities of Oleandrin.Approved, Vet Approved
PyrazoloacridineOleandrin may decrease the cardiotoxic activities of Pyrazoloacridine.Investigational
QuinacrineOleandrin may decrease the cardiotoxic activities of Quinacrine.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Oleandrin.Approved
QuinidineThe serum concentration of Oleandrin can be increased when it is combined with Quinidine.Approved
RabusertibOleandrin may decrease the cardiotoxic activities of Rabusertib.Investigational
Radium Ra 223 DichlorideOleandrin may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedOleandrin may decrease the cardiotoxic activities of Raltitrexed.Approved, Investigational
RamucirumabOleandrin may decrease the cardiotoxic activities of Ramucirumab.Approved, Investigational
RanibizumabOleandrin may decrease the cardiotoxic activities of Ranibizumab.Approved
RanimustineOleandrin may decrease the cardiotoxic activities of Ranimustine.Experimental
RanpirnaseOleandrin may decrease the cardiotoxic activities of Ranpirnase.Investigational
RapacuroniumRapacuronium may increase the arrhythmogenic activities of Oleandrin.Withdrawn
RegorafenibOleandrin may decrease the cardiotoxic activities of Regorafenib.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Oleandrin.Approved, Investigational
ResveratrolOleandrin may decrease the cardiotoxic activities of Resveratrol.Approved, Experimental, Investigational
Rhodamine 6GOleandrin may decrease the cardiotoxic activities of Rhodamine 6G.Experimental
RibostamycinThe serum concentration of Oleandrin can be decreased when it is combined with Ribostamycin.Approved, Investigational
RidaforolimusOleandrin may decrease the cardiotoxic activities of Ridaforolimus.Investigational
RituximabOleandrin may decrease the cardiotoxic activities of Rituximab.Approved
RocuroniumRocuronium may increase the arrhythmogenic activities of Oleandrin.Approved
RomidepsinOleandrin may decrease the cardiotoxic activities of Romidepsin.Approved, Investigational
RoquinimexOleandrin may decrease the cardiotoxic activities of Roquinimex.Investigational
RubitecanOleandrin may decrease the cardiotoxic activities of Rubitecan.Investigational
RucaparibOleandrin may decrease the cardiotoxic activities of Rucaparib.Approved, Investigational
RufloxacinOleandrin may decrease the cardiotoxic activities of Rufloxacin.Experimental
RuxolitinibOleandrin may decrease the cardiotoxic activities of Ruxolitinib.Approved
SabarubicinThe serum concentration of Oleandrin can be decreased when it is combined with Sabarubicin.Investigational
SalirasibOleandrin may decrease the cardiotoxic activities of Salirasib.Investigational
SaracatinibOleandrin may decrease the cardiotoxic activities of Saracatinib.Investigational
SatraplatinOleandrin may decrease the cardiotoxic activities of Satraplatin.Investigational
SeliciclibOleandrin may decrease the cardiotoxic activities of Seliciclib.Investigational
SemaxanibOleandrin may decrease the cardiotoxic activities of Semaxanib.Investigational
SemustineOleandrin may decrease the cardiotoxic activities of Semustine.Experimental, Investigational
SeocalcitolOleandrin may decrease the cardiotoxic activities of Seocalcitol.Experimental, Investigational
SiltuximabOleandrin may decrease the cardiotoxic activities of Siltuximab.Approved
SirolimusOleandrin may decrease the cardiotoxic activities of Sirolimus.Approved, Investigational
SisomicinThe serum concentration of Oleandrin can be decreased when it is combined with Sisomicin.Investigational
SitafloxacinOleandrin may decrease the cardiotoxic activities of Sitafloxacin.Experimental, Investigational
SizofiranOleandrin may decrease the cardiotoxic activities of Sizofiran.Investigational
SoblidotinOleandrin may decrease the cardiotoxic activities of Soblidotin.Investigational
SolithromycinThe serum concentration of Oleandrin can be increased when it is combined with Solithromycin.Investigational
SonidegibOleandrin may decrease the cardiotoxic activities of Sonidegib.Approved, Investigational
SorafenibOleandrin may decrease the cardiotoxic activities of Sorafenib.Approved, Investigational
SotalolSotalol may increase the bradycardic activities of Oleandrin.Approved
SP1049CThe serum concentration of Oleandrin can be decreased when it is combined with SP1049C.Investigational
SparfloxacinOleandrin may decrease the cardiotoxic activities of Sparfloxacin.Approved, Investigational
Sparfosic acidOleandrin may decrease the cardiotoxic activities of Sparfosic acid.Experimental
SparsomycinOleandrin may decrease the cardiotoxic activities of Sparsomycin.Experimental
SpectinomycinThe serum concentration of Oleandrin can be decreased when it is combined with Spectinomycin.Approved, Investigational, Vet Approved
SpiramycinThe serum concentration of Oleandrin can be increased when it is combined with Spiramycin.Approved
SpironolactoneThe therapeutic efficacy of Oleandrin can be decreased when used in combination with Spironolactone.Approved
squalamineOleandrin may decrease the cardiotoxic activities of squalamine.Investigational
SRT501Oleandrin may decrease the cardiotoxic activities of SRT501.Investigational
StreptomycinThe serum concentration of Oleandrin can be decreased when it is combined with Streptomycin.Approved, Vet Approved
StreptozocinOleandrin may decrease the cardiotoxic activities of Streptozocin.Approved
SuccinylcholineSuccinylcholine may increase the arrhythmogenic activities of Oleandrin.Approved
SulforaphaneOleandrin may decrease the cardiotoxic activities of Sulforaphane.Investigational
SulindacOleandrin may decrease the cardiotoxic activities of Sulindac.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oleandrin.Approved, Investigational
SunitinibOleandrin may decrease the cardiotoxic activities of Sunitinib.Approved, Investigational
SuraminOleandrin may decrease the cardiotoxic activities of Suramin.Approved, Investigational
TalaporfinOleandrin may decrease the cardiotoxic activities of Talaporfin.Investigational
TalazoparibOleandrin may decrease the cardiotoxic activities of Talazoparib.Investigational
TalinololTalinolol may increase the bradycardic activities of Oleandrin.Investigational
TamoxifenOleandrin may decrease the cardiotoxic activities of Tamoxifen.Approved
TaselisibOleandrin may decrease the cardiotoxic activities of Taselisib.Investigational
TaurolidineOleandrin may decrease the cardiotoxic activities of Taurolidine.Investigational
TegafurOleandrin may decrease the cardiotoxic activities of Tegafur.Approved
TelithromycinThe serum concentration of Oleandrin can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Oleandrin can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinOleandrin may decrease the cardiotoxic activities of Temafloxacin.Withdrawn
TemoporfinOleandrin may decrease the cardiotoxic activities of Temoporfin.Approved, Investigational
TemozolomideOleandrin may decrease the cardiotoxic activities of Temozolomide.Approved, Investigational
TemsirolimusOleandrin may decrease the cardiotoxic activities of Temsirolimus.Approved
TeniposideOleandrin may decrease the cardiotoxic activities of Teniposide.Approved
TertatololTertatolol may increase the bradycardic activities of Oleandrin.Experimental
TestolactoneOleandrin may decrease the cardiotoxic activities of Testolactone.Approved, Investigational
TezacitabineOleandrin may decrease the cardiotoxic activities of Tezacitabine.Investigational
ThalidomideOleandrin may decrease the cardiotoxic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiotepaOleandrin may decrease the cardiotoxic activities of Thiotepa.Approved
ThymalfasinOleandrin may decrease the cardiotoxic activities of Thymalfasin.Approved, Investigational
TiazofurineOleandrin may decrease the cardiotoxic activities of Tiazofurine.Experimental
TiboloneOleandrin may decrease the cardiotoxic activities of Tibolone.Approved, Investigational
TimololTimolol may increase the bradycardic activities of Oleandrin.Approved
TioguanineOleandrin may decrease the cardiotoxic activities of Tioguanine.Approved
Tiomolibdate ionOleandrin may decrease the cardiotoxic activities of Tiomolibdate ion.Investigational
TipifarnibOleandrin may decrease the cardiotoxic activities of Tipifarnib.Investigational
TirapazamineOleandrin may decrease the cardiotoxic activities of Tirapazamine.Investigational
TivozanibOleandrin may decrease the cardiotoxic activities of Tivozanib.Investigational
TobramycinThe serum concentration of Oleandrin can be decreased when it is combined with Tobramycin.Approved, Investigational
TolevamerThe risk or severity of adverse effects can be increased when Tolevamer is combined with Oleandrin.Approved
TopotecanOleandrin may decrease the cardiotoxic activities of Topotecan.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Oleandrin.Approved
ToremifeneOleandrin may decrease the cardiotoxic activities of Toremifene.Approved, Investigational
TositumomabOleandrin may decrease the cardiotoxic activities of Tositumomab.Approved, Investigational
TrabectedinOleandrin may decrease the cardiotoxic activities of Trabectedin.Approved, Investigational
TrametinibOleandrin may decrease the cardiotoxic activities of Trametinib.Approved
TrastuzumabOleandrin may decrease the cardiotoxic activities of Trastuzumab.Approved, Investigational
Trastuzumab emtansineOleandrin may decrease the cardiotoxic activities of Trastuzumab emtansine.Approved
TrebananibOleandrin may decrease the cardiotoxic activities of Trebananib.Investigational
TremelimumabOleandrin may decrease the cardiotoxic activities of Tremelimumab.Investigational
TreosulfanOleandrin may decrease the cardiotoxic activities of Treosulfan.Investigational
TretazicarOleandrin may decrease the cardiotoxic activities of Tretazicar.Investigational
TretinoinOleandrin may decrease the cardiotoxic activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe therapeutic efficacy of Oleandrin can be decreased when used in combination with Triamterene.Approved
TriaziquoneOleandrin may decrease the cardiotoxic activities of Triaziquone.Experimental
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Oleandrin.Approved, Vet Approved
TrilostaneOleandrin may decrease the cardiotoxic activities of Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimetrexateOleandrin may decrease the cardiotoxic activities of Trimetrexate.Approved, Investigational
TriptolideOleandrin may decrease the cardiotoxic activities of Triptolide.Investigational
TriptorelinOleandrin may decrease the cardiotoxic activities of Triptorelin.Approved, Vet Approved
TrofosfamideOleandrin may decrease the cardiotoxic activities of Trofosfamide.Investigational
TrovafloxacinOleandrin may decrease the cardiotoxic activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxacitabineOleandrin may decrease the cardiotoxic activities of Troxacitabine.Investigational
TubercidinOleandrin may decrease the cardiotoxic activities of Tubercidin.Experimental
TubocurarineTubocurarine may increase the arrhythmogenic activities of Oleandrin.Approved
TylosinThe serum concentration of Oleandrin can be increased when it is combined with Tylosin.Vet Approved
UbenimexOleandrin may decrease the cardiotoxic activities of Ubenimex.Experimental, Investigational
Uracil mustardOleandrin may decrease the cardiotoxic activities of Uracil mustard.Approved
VadimezanOleandrin may decrease the cardiotoxic activities of Vadimezan.Investigational
ValrubicinOleandrin may decrease the cardiotoxic activities of Valrubicin.Approved
VandetanibOleandrin may decrease the cardiotoxic activities of Vandetanib.Approved
VapreotideOleandrin may decrease the cardiotoxic activities of Vapreotide.Approved, Investigational
VecuroniumVecuronium may increase the arrhythmogenic activities of Oleandrin.Approved
VeliparibOleandrin may decrease the cardiotoxic activities of Veliparib.Investigational
VemurafenibOleandrin may decrease the cardiotoxic activities of Vemurafenib.Approved
VerapamilVerapamil may increase the atrioventricular blocking (AV block) activities of Oleandrin.Approved
VerteporfinOleandrin may decrease the cardiotoxic activities of Verteporfin.Approved, Investigational
VesnarinoneOleandrin may decrease the cardiotoxic activities of Vesnarinone.Investigational
VinblastineOleandrin may decrease the cardiotoxic activities of Vinblastine.Approved
VincristineOleandrin may decrease the cardiotoxic activities of Vincristine.Approved, Investigational
VindesineOleandrin may decrease the cardiotoxic activities of Vindesine.Approved, Investigational
VinflunineOleandrin may decrease the cardiotoxic activities of Vinflunine.Approved
VinorelbineOleandrin may decrease the cardiotoxic activities of Vinorelbine.Approved, Investigational
VintafolideOleandrin may decrease the cardiotoxic activities of Vintafolide.Investigational
VismodegibOleandrin may decrease the cardiotoxic activities of Vismodegib.Approved
Vitamin AOleandrin may decrease the cardiotoxic activities of Vitamin A.Approved, Nutraceutical, Vet Approved
VorinostatOleandrin may decrease the cardiotoxic activities of Vorinostat.Approved, Investigational
VorozoleOleandrin may decrease the cardiotoxic activities of Vorozole.Experimental
Zoptarelin doxorubicinThe serum concentration of Oleandrin can be decreased when it is combined with Zoptarelin doxorubicin.Investigational
ZorubicinOleandrin may decrease the cardiotoxic activities of Zorubicin.Experimental
Zuretinol acetateOleandrin may decrease the cardiotoxic activities of Zuretinol acetate.Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
11541511
PubChem Substance
347829006
ChemSpider
9716290
ChEBI
59030
ChEMBL
CHEMBL1075789
Wikipedia
Oleandrin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1WithdrawnTreatmentChemotherapeutic Agent Toxicity / Lung Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00299 mg/mLALOGPS
logP2.1ALOGPS
logP2.95ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)6.82ChemAxon
pKa (Strongest Basic)-3.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area120.75 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity148.45 m3·mol-1ChemAxon
Polarizability63.2 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid lactones
Direct Parent
Cardenolide glycosides and derivatives
Alternative Parents
Steroidal glycosides / Steroid esters / 14-hydroxysteroids / Hexoses / O-glycosyl compounds / Oxanes / Butenolides / Dicarboxylic acids and derivatives / Tertiary alcohols / Enoate esters
show 9 more
Substituents
Cardanolide-glycoside / Steroidal glycoside / Steroid ester / 14-hydroxysteroid / Hydroxysteroid / Hexose monosaccharide / Glycosyl compound / O-glycosyl compound / 2-furanone / Dicarboxylic acid or derivatives
show 23 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
steroid ester, steroid saponin, 14beta-hydroxy steroid, cardenolide glycoside (CHEBI:59030)

Drug created on October 20, 2016 18:39 / Updated on November 09, 2017 05:13